Industry top-down
Biotechnology
Latest reported revenue & EPS across the covered companies in this industry, with year-over-year (YoY) change. From disclosed earnings — not investment advice.
AI industry top-down
The biotechnology industry exhibited significant disparities in sales performance across companies. While some companies achieved high sales growth rates of over 40%, others experienced double-digit sales declines. The industry's median sales growth rate stood at approximately 19.2%, though this figure reflects the varied performance of individual companies. Limited EPS data makes it difficult to ascertain overall profitability trends.
- Some companies achieved high revenue growth rates
- Other companies experienced revenue decline or stagnation
- Lack of EPS data limits profitability assessment
AI synthesis of disclosed results and analyst research across these companies — not investment advice.
Companies — latest quarter
| Company | Period | Revenue | Rev YoY | EPS | EPS YoY | Surprise |
|---|---|---|---|---|---|---|
| REGNREGENERON PHARMACEUTICALS, INC. | FY2026 Q1 | $3.03B | -3.7% | $7.27 | +15.9% | — |
| ALNYALNYLAM PHARMACEUTICALS, INC. | FY2025 Q3 | $1.66B | +19.2% | $-1.53 | — | — |
| BEIGFBeOne Medicines Ltd. | FY2026 Q1 | $1.12B | +48.6% | $0.00 | — | — |
| ONCBeOne Medicines Ltd. | FY2026 Q1 | $1.12B | +48.6% | $0.00 | — | — |
| INSMINSMED Inc | FY2026 Q1 | $92.82M | +22.9% | $-1.42 | — | — |
| INCYINCYTE CORP | FY2026 Q1 | $1.05B | +19.5% | $0.80 | +6.7% | — |
| MRNAModerna, Inc. | FY2026 Q1 | $108M | -35.3% | $-2.52 | — | — |
| JAZZJazz Pharmaceuticals plc | FY2026 Q1 | $897.8M | -0.5% | $-1.52 | — | — |
| BBIOBridgeBio Pharma, Inc. | FY2026 Q1 | $116.63M | -44.8% | $-0.88 | — | — |
| EXELEXELIXIS, INC. | FY2026 Q1 | $555.45M | +30.6% | $0.55 | — | — |
| IONSIONIS PHARMACEUTICALS INC | FY2026 Q1 | $131.61M | +10.1% | $-0.93 | — | — |
| AXSMAxsome Therapeutics, Inc. | FY2026 Q1 | $121.46M | +62.0% | $-1.22 | — | — |
| MDGLMADRIGAL PHARMACEUTICALS, INC. | FY2026 Q1 | $137.25M | — | $-17.33 | — | — |
| ARWRARROWHEAD PHARMACEUTICALS, INC. | FY2026 Q2 | $545.21M | — | $1.52 | — | — |
| BMRNBIOMARIN PHARMACEUTICAL INC | FY2026 Q1 | $745.15M | +14.8% | $0.95 | +106.5% | — |
| CYTKCYTOKINETICS INC | FY2026 Q1 | $1.58M | +89.1% | $-1.36 | — | — |
| PRAXPraxis Precision Medicines, Inc. | FY2025 Q3 | $1.09M | -43.6% | $-7.21 | — | — |
| KRYSKrystal Biotech, Inc. | FY2026 Q1 | $88.18M | +94.9% | $1.20 | — | — |
| HALOHALOZYME THERAPEUTICS, INC. | FY2026 Q1 | $264.86M | +35.2% | $0.93 | +55.0% | — |
| IBRXImmunityBio, Inc. | FY2026 Q1 | $16.52M | — | $-0.15 | — | — |
YoY = vs. the same quarter last year · Surprise = EPS actual vs. consensus. Latest reported quarter per company, from disclosed earnings filings. QoQ is omitted because quarterly filings don’t break out Q4 (US) and report cumulatively (KR).